The Pediatric Optic Neuritis Prospective Outcomes Study – Two-Year Results
Stacy L. Pineles,Robert J. Henderson,Michael X. Repka,Gena Heidary,Grant T. Liu,Amy T. Waldman,Mark S. Borchert,Sangeeta Khanna,Jennifer S. Graves,Janine E. Collinge,Julie A. Conley,Patricia L. Davis,Raymond T. Kraker,Susan A. Cotter,Jonathan M. Holmes,Pediatric Eye Disease Investigator Group,Mark S. Borchert,Melinda Y. Chang,Dilshad Contractor,Emily J. Zolfaghari,Aarti Vyas,Tiffany Yuen,Veeral S. Shah,Evelyn A. Paysse,Gihan Romany,Jason H. Peragallo,Judy L. Brower,Aparna Raghuram,Gena Heidary,Bilal Al Wattar,Ryan Chinn,Srishti Kothari,R. Michael Siatkowski,Janine E. Collinge,Maria E. Lim,Alisha N. Brewer,Annette M. Doughty,Sonny W. Icks,Shannon Almeida,Alejandra de Alba Campomanes,Premilla Banwait,Jennifer S. Graves,Leila Hajkazemshirazi,Yizhuo Bastea-Forte,Jennifer K. Arjona,Jeremy Chen,Karen Cooper,Rafif Ghadban,Sophia M. Chung,Oscar A. Cruz,Sangeeta Khanna,Traci A. Christenson,Lisa L. Breeding,Dawn M. Govreau,Beth A. Wallis,Brooke E. Geddie,Julie A. Conley,Elisabeth T. Wolinski,Patricia L. Davis,Indre M. Rudaitis,Jacqueline Twite,Carrie S. Bloomquist,Sarah R. Laboy,Jackie M. Twite,Stacy L. Pineles,Michelle V. Doan,Marianne J. Bernardo,Michael C. Brodsky,John J. Chen,Jonathan M. Holmes,Suzanne M. Wernimont,Lindsay L. Czaplewski,Stacy L. Eastman,Moriah A. Keehn,Debbie M. Priebe,Don L. Bremer,Richard P. Golden,Catherine O. Jordan,Mary Lou McGregor,Rachel E. Reem,David L. Rogers,Amanda N. Schreckengost,Sara A. Maletic,Mays A. Dairi,Laura B. Enyedi,Sarah K. Jones,Navajyoti R. Barman,Robert J. House,David A. Nasrazadani,Sean M. Gratton,Justin D. Marsh,Rebecca J. Dent,Lezlie L. Bond,Lori L. Soske,Padmaja Sudhakar,Christi M. Willen,Deborah Taylor,Nathaniel Q. Moliterno,Michael Nsoesie,Shaista Vally,Paul H. Phillips,Robert S. Lowery,Beth Colon,Nancy L. Stotts,Kelly D. To,Collin M. McClelland,Raymond G. Areaux,Ann M. Holleschau,Kim S. Merrill,Luis H. Ospina,Rosanne Superstein,Maryse Thibeault,Helene Gagnon,Sean P. Donahue,Scott T. Ruark,Lisa A. Fraine,Petrice A. Sprouse,Ronald J. Biernacki,Grant T. Liu,Robert A. Avery,Brian J. Forbes,Imran Jivraj,Anita A. Kohli,Meg M. Richter,Agnieshka Baumritter,Ellen B. Mitchell,Ken K. Nischal,Lauren M. Runkel,Bianca Blaha,Whitney Churchfield,Christina Fulwylie,Melissa W. Ko,Luis J. Mejico,Muhammad Iqbal,Catherine E. Attanasio,Lena F. Deb,Courtney B. Goodrich,Alisha M. Hartwell,Jennifer A. Moore,Lisa Bohra,Alexandra O. Apkarian,Elena M. Gianfermi,John D. Roarty,Leemor B. Rotberg,Susan N. Perzyk,Raymond T. Kraker,Roy W. Beck,Darrell S. Austin,Nicole M. Boyle,Danielle L. Chandler,Patricia L. Connelly,Courtney L. Conner,Trevano W. Dean,Quayleen Donahue,Brooke P. Fimbel,Robert J. Henderson,Amra Hercinovic,James E. Hoepner,Joseph D. Kaplon,Zhuokai Li,Gillaine Ortiz,Julianne L. Robinson,Kathleen M. Stutz,David O. Toro,Victoria C. Woodard,Rui Wu,Michael X. Repka,Laura Balcer,Mark Kupersmith,Elizabeth L. Lazar,Amy Waldman,David K. Wallace,Susan A. Cotter,Eileen E. Birch,Angela M. Chen,Stephen P. Christiansen,S. Ayse Erzurum,Donald F. Everett,Sharon F. Freedman,William V. Good,Katherine A. Lee,Richard London,Vivian M. Manh,Ruth E. Manny,David G. Morrison,Bonita R. Schweinler,Jayne L. Silver,Lisa C. Verderber,Katherine K. Weise,Ari Green,Marie Diener-West,John D. Baker,Barry Davis,Dale L. Phelps,Stephen W. Poff,Richard A. Saunders,Lawrence Tychsen
DOI: https://doi.org/10.1016/j.ophtha.2022.03.021
IF: 14.277
2022-03-01
Ophthalmology
Abstract:PurposePediatric optic neuritis (ON) is a rare disease that has not been well characterized. The pediatric ON prospective outcomes study (PON1) was the first prospective study aiming to evaluate visual acuity (VA) outcomes, including VA, recurrence risk, and final diagnosis 2-years post-enrollmentDesignNon-randomized observational study at 23 pediatric ophthalmology or neuro-ophthalmology clinics in US and Canada.Participants28 (64%) of 44 children initially enrolled in PON1 (age 3<16 years) who completed their 2-year study visit.Exposure(s)Treatment at investigator discretion.Main Outcomes MeasuresAge-normal monocular high contrast VA (HCVA). Secondary outcomes included low contrast VA (LCVA), neuroimaging findings, and final diagnoses.Results28 participants completed the 2-year outcome with a median enrollment age of 10.3 years (range 5-15); 46% were female and 68% had unilateral ON at presentation. Final 2-year diagnoses included isolated ON (n=11, 40%), myelin oligodendrocyte glycoprotein (MOG)-associated demyelination (n=8, 29%), multiple sclerosis (MS) (n=4,14%), neuromyelitis optica spectrum disease (NMOSD) (n=3,11%), and acute disseminated encephalomyelitis (n=2, 7%). Two (7%; 95% CI=1-24%) participants had subsequent recurrent ON (plus one participant who did not complete the 2-year visit); all had MS. Two other participants (7%) had a new episode in their unaffected eye. Mean presenting HCVA was 0.81 logMAR (∼20/125), improving to 0.14 logMAR (∼20/25-2) at 6 months, 0.12 logMAR (∼20/25-2) at 1 year, and 0.11 logMAR (20/25-1) at 2 years (95% CI=-0.08-0.3 (20/20+1-20/40-1)). Twenty-four (79%) had age-normal VA at 2 years (95% CI=60-90%);21 (66%) had 20/20 vision or better. The six participants without age-normal VA had 2-year diagnoses of NMOSD (n=2 participants, 3 eyes), MS (n=2 participants, 2 eyes), and isolated ON (n=2 participants, 3 eyes). Mean presenting LCVA was 1.45 logMAR (∼20/500-2), improving to 0.78 logMAR (∼20/125+2) at 6 months, 0.69 logMAR (∼20/100+1) at 1 year, and 0.68 logMAR (∼20/100+2) at 2 years (95% CI=0.48-0.88 (20/50+1-20/150-1)).ConclusionsDespite poor VA at presentation, most children had marked improvement in VA by 6 months which was maintained over two years. Associated neurologic autoimmune diagnoses were common. Additional episodes of ON occurred in 5 (18%) of the participants (3 relapses and 2 new episodes).
ophthalmology